Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company that entered the public market in 2023, is gearing up for a year filled with data-driven advancements in 2024.
The company is focused on developing novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. It has a broad pipeline comprising of 3 clinical-stage assets and a couple of preclinical compounds addressing some of the most prevalent brain health disorders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com